The FDA Already Proved Our Point

An Investor Case for CellSonic VIPP and Sapiens Shield

Prepared by Mehdi El Harti
Business Development | CellSonic Ltd.
mehdi@cellsonicglobal.com | cellsonicltd.com
April 2026

Technology by Professor Andrew Hague, Founder, CellSonic Ltd.

I. The Statement

Cancer is not a mystery. It is a voltage fault.

When the electrical charge across a cell membrane drops below a critical threshold, the cell loses its ability to replicate correctly and begins dividing without control. That is cancer. Not a genetic accident requiring a chemical solution. An electrical failure requiring an electrical correction.

This has been known since 1970. It has been demonstrated independently by scientists on three continents across nine decades. And in February 2026, the FDA validated it for the fourth time, in the form of an approved competitor technology called Novocure Tumor Treating Fields.

The objection raised against CellSonic for twenty years has been that the mechanism is not proven to the satisfaction of the medical establishment. That argument collapsed the moment the FDA approved a device whose own researchers state plainly in peer-reviewed journals that the precise mechanism is not fully understood. The FDA approved it anyway. Results were enough.

CellSonic has understood the mechanism for 37 years.

The Core Position

CellSonic VIPP and Novocure Tumor Treating Fields share the same foundational science. Both correct an electrical fault in cancer cells. The difference is delivery, duration, cost, scope, and mechanism comprehension.

Novocure applies a low-level alternating field for 18 hours every day over months and treats four cancers. CellSonic fires a 25,000-volt nanosecond electromagnetic burst combined with intense pressure in under two minutes and has documented outcomes across 38 conditions.

Novocure charges $27,000 per patient per month. Their 2025 annual revenue was $655 million. They remain loss-making after 25 years. Only 4,620 patients are on therapy worldwide today.

That is what the trial route costs. And that is what CellSonic chose to avoid.

II. What the FDA Did in February 2026

Novocure was founded in the year 2000. Its founder, Professor Yoram Palti of the Technion Institute in Israel, retrieved a 40-year-old doctoral thesis on electric fields in nerve fibres and applied the principle to cancer. He set up a laboratory in the basement of his home in Haifa. No medical school. No pharmaceutical backing. A physicist following the evidence.

The company spent years running Phase III clinical trials. Competitors attempting the same trial-based route went bankrupt. HMT High Medical Technologies AG in Switzerland is one documented example. The trial process consumed capital at a rate that destroyed companies before results could be demonstrated.

In 2011, Novocure received its first FDA approval for glioblastoma, the most aggressive form of brain cancer, which carries a five-year survival rate of under ten percent. With TTFields, that survival rate tripled. The mechanism at the point of approval was stated as not fully explained. It remains incompletely explained in 2026.

> *The precise molecular mechanisms underlying the effects of TTFields are not fully understood and some concepts remain controversial.*
>
> **Expert Review of Molecular Diagnostics, 2022 | Peer-reviewed mechanism summary**

> *The exact biophysical mechanisms of TTFields on mitotic cells are not completely understood and more research is necessary.*
>
> **Nature Scientific Reports, 2019**

Between 2011 and February 2026, the FDA approved TTFields for four cancer types. Brain tumours, mesothelioma, non-small cell lung cancer, and pancreatic cancer. Each approval was granted on the basis of clinical results. The mechanism explanation was secondary. Results were enough.

The Financial Reality of the Trial Route

Novocure's 2025 financial results, published by the company on its own investor relations page, tell a story that every investor in electrical medicine should understand.

$655 million in 2025 annual revenue

Still reporting a net loss every single quarter of 2025

Only 4,620 patients on therapy worldwide after 25 years and four FDA approvals

Projected to remain unprofitable for at least three more years

Source: Novocure Q4 and Full Year 2025 Financial Results, February 26, 2026

That is the cost of the trial route. A quarter of a century of work. Four FDA approvals. $655 million in annual revenue. Still unable to turn a profit. Still serving fewer than five thousand patients globally.

This is not a criticism of Novocure. It is a demonstration of why CellSonic chose a different path. The science works. The trial route is financially and structurally broken for anyone without unlimited capital and decades to burn.

III. A Century of Independent Convergence

The most powerful evidence for the electrical theory of cancer is not any single scientist's work. It is what happens when you look at all of them together.

Five scientists. Four countries. Nine decades. No collaboration. No shared funding. No awareness of each other when each reached their conclusions. All of them arrived at the same place.

When independent researchers working in isolation arrive at the same scientific conclusion, that is not coincidence. That is science confirming itself.

Period	Scientist	Country	What the Record Shows
1930s	Royal Rife	USA	Built a microscope capable of viewing living viruses. Demonstrated that specific electromagnetic frequencies caused cancer cells to self-destruct selectively without touching healthy tissue. Forty-four physicians witnessed clinical results in 1934. Within a decade, all documentation had been lost or destroyed under disputed circumstances. He died in 1971. The scientific principle he demonstrated has since been validated in laboratory settings by multiple independent researchers.
1983	Bjorn Nordenstrom	Sweden	Former Chairman of the Nobel Prize Assembly for Medicine. Published Biologically Closed Electric Circuits at the Karolinska Institute. Documented that healthy cells maintain a membrane potential of approximately minus 70mV and cancer cells drop to approximately minus 15mV. Treated 26 tumours across 20 inoperable lung cancer patients: 12 tumours disappeared or markedly reduced over a 2 to 5 year follow-up. His findings were subsequently replicated across more than 20,000 patients in China with Ministry of Public Health approval. Largely ignored by Western oncology.
1987	Andrew Hague	United Kingdom	Working independently from lithotripsy engineering at St Thomas' Hospital, London. No knowledge of Rife. No knowledge of Nordenstrom at the time of his work. Independently identified cancer as an electrical voltage fault and developed CellSonic VIPP to correct it. The first cancer patient treated in 2016 remains alive and in normal health today.
2000	Yoram Palti	Israel	Professor of physiology and biophysics at the Technion Institute. Retrieved a 40-year-old doctoral thesis on electric fields in nerve fibres and applied the principle to cancer. Founded Novocure. Reached the same conclusion about electrical fields and cancer independently. No documented awareness of Rife or Nordenstrom at founding. FDA approved in 2011. Now approved for four cancer types.

The convergence of these four independent lines of work constitutes something the medical establishment has not been able to produce in a century of chemotherapy research:

reproducible, mechanism-consistent evidence across unconnected researchers and institutions that cancer is an electrical problem with an electrical solution.

None of them needed the others to get there. That is the point.

IV. What Conventional Oncology Does to the Body

This section does not contain claims made by CellSonic. It documents findings from peer-reviewed research compiled by Dr. Glen Halls PhD in his 2025 independent literature review, drawing on 44 published studies. The sources include The Lancet, the National Center for Biotechnology Information, and journals published on ResearchGate. Every study cited is independently verifiable.

The core finding across all 44 studies is consistent: the three pillars of conventional oncology create biological conditions in which cancer is more likely to recur, not less.

Chemotherapy: Voltage Depletion

Chemotherapy targets rapidly dividing cells without discrimination. It does not distinguish between cancer cells and the intestinal lining, bone marrow, and healthy organ tissue that the body depends on for recovery.

Finding	Source
Up to 100% of high-dose patients suffer complete destruction of intestinal villi, depleting the potassium and magnesium required to maintain cell voltage.	PMC10033220, 2023
Chemotherapy imposes a permanent somatic mutation load on healthy stem cells, inducing accelerated biological ageing in surrounding tissue.	PMC12283364, 2025
Irreversible fibrosis in liver and kidneys creates tissue where electrical flow is resisted, grounding the body's healing current.	PMC8833520, 2022
Permanent destruction of thyroid and adrenal glands ensures the body can no longer produce the metabolic potential required to maintain healthy cell voltage.	PMID 28661901, 2017

Radiation: The Fibrotic Fortress

Radiation converts healthy, electrically conductive tissue into rigid, insulating fibrosis. This creates what the published literature calls immune sanctuaries: zones of hardened tissue that physically block the immune system from reaching remaining cancer cells while providing them a shielded environment to survive and regroup.

Finding	Source
Radiation permanently deletes repair capacity in local tissue through stem cell exhaustion, leading to irreversible late-stage fibrosis where electrical signalling stops at the treated border.	Verginadis et al., The Lancet, 2025

Finding	Source
Radiation-induced hypoxia and vascular damage reprogramme local immune cells to become immunosuppressive, effectively hiding malignancy from the body's own defences.	Guo et al., 2023
Surgical scars have measurably higher electrical resistance than normal skin, acting as a dam stopping the body's healing current from reaching areas that need it.	NeuroVeda Health, 2025

Surgery: The Fibrin Trap

Surgery severs the body's electrical circuits, triggers emergency repair responses that cancer cells have evolved to exploit, and deposits fibrin on scar zones that function as landing strips for circulating tumour cells.

Finding	Source
Surgical injury deposits fibrin on scar zones. These deposits capture circulating tumour cells and allow them to anchor in previously healthy organs.	Al dybiat et al., 2020
Surgical trauma releases VEGF and IL-6 growth factors that activate dormant micrometastases in distant parts of the body.	Jiao and Lv, 2023
Neutrophil extracellular traps triggered by surgery catch mobile cancer cells and seed them into lungs and liver.	Kwak et al., 2022

> *The conclusion is obvious. You cannot poison your way to health if the underlying electrical hardware is broken. The only path to resolution is to restore the bio-electrical terrain.*
>
> **Dr. Glen Halls PhD, The Architectural Betrayal, 2025**

CellSonic does not poison. It does not irradiate. It does not cut. It restores voltage. That is a fundamentally different category of intervention.

V. The Science: Why CellSonic Works

CellSonic VIPP delivers four forces simultaneously in a pulse lasting one billionth of a second: a very intense pressure wave, light across a spectrum of frequencies, an electromagnetic field generated by 25,000 volts crossing a one-millimetre gap, and electrolysis. Novocure delivers one force continuously for 18 hours a day. That is not a matter of preference. It is a structural difference in the physics.

Pressure	Electromagnetic Field	Light	Electrolysis
Kills infection, promotes tissue and bone regeneration, dismantles fibrotic barriers	25,000 volts restoring cancer cell voltage from minus 15mV to minus 75mV in under 50 seconds	Full spectrum frequencies from low to very high delivered simultaneously	Produces oxygen at treatment site to kill infection and hydrogen to promote vascular regeneration

The Safety Foundation

The pressure wave component of VIPP is not new science. Lithotripsy, the use of focused pressure pulses to destroy kidney stones without surgery, has been in clinical use for nearly forty years across hospitals in most countries in the world. Millions of patients. No systemic side effects documented from the pressure wave itself. CellSonic evolved directly from this foundation.

That is a safety record no clinical trial could produce. Forty years of real-world use across millions of patients in every major healthcare system on earth. Novocure had none of this when it sought FDA approval in 2011. CellSonic had it before the first cancer treatment was ever attempted.

The Published Synergy

A study indexed in PubMed in 2007 demonstrated that the synchronous application of electric field and shockwave reduces cancer cell survival fivefold compared to either force applied alone. The compression phase of the shockwave amplifies the effectiveness of the electric field at a cellular level, reducing the field intensity required to breach the cell membrane. That is the published physics behind applying both forces together. That is VIPP.

Novocure applies one force. CellSonic applies four. The published literature confirms the combination is not additive. It is synergistic.

The Voltage Rule

The mechanism of action is the restoration of transmembrane voltage. Healthy cells maintain a membrane potential of approximately minus 70mV to minus 75mV. Cancer cells are consistently measured at minus 10mV to minus 15mV. At that voltage, the cell switches from oxygen-based repair to fermentation, the metabolic state of malignancy.

This is not a theory. It is documented in a NASA technical paper by C.D. Cone Jr. from 1970, in Nordenstrom's Karolinska research from 1983, in Dr. Steve Haltiwanger's paper on the electrical properties of cancer cells, and confirmed in the NIH's own published literature on membrane potential and cancer progression.

CellSonic lifts that voltage in under 50 seconds. Novocure, by contrast, makes no mention of cell voltage in its clinical documentation and states its own mechanism is not fully understood.

VI. CellSonic vs Novocure: The Facts

Every figure in this comparison is independently verifiable. Novocure financial data is drawn from the company's own published quarterly results. FDA approval history is drawn from the FDA's public record. Cost data is sourced from the National Center for Biotechnology Information.

The FDA approved Novocure. But that is not the full picture. The European Union granted CE Mark approval. Japan's Ministry of Health approved it. China approved it. Ten countries Austria, Czechia, France, Germany, Israel, Japan, Spain, Sweden, Switzerland and the United States have assessed the evidence and decided it is worth paying for from public health budgets.

Category	Novocure TTFields	CellSonic VIPP
FDA approval status	Approved: brain, lung, mesothelioma, pancreatic	CE marked | ISO 13485:2016 | ISO 9001:2017 | FDA registered 3017514970
Treatment duration	18 hours per day, every day, for months	Under two minutes per session
Cost to the healthcare system	$27,000 per patient per month (NCBI confirmed)	Session fee set by treating clinic
Mechanism explained?	Not fully understood (stated in multiple peer-reviewed journals)	Cell voltage restoration understood and documented since 1987
Voltage diagnosis	Not mentioned in clinical documentation	Measured and recorded before and after every treatment
Forces delivered	One: alternating electric field	Four simultaneously: pressure, EM field, light, electrolysis
Drug dependency	Often combined with chemotherapy	No drugs required.
Side effects	Skin irritation, fatigue, nausea when combined with chemo	None documented from the technology itself
Conditions treated	4 cancer types	38 documented conditions including multiple cancers
Safety foundation	Phase III trial data since 2004	40 years of lithotripsy across millions of patients globally
Revenue model	Device rental per patient. Revenue ends when treatment stops.	Machine sold once. Recurring revenue from shock heads indefinitely.
Company profitability	Still loss-making after 25 years and $655M annual revenue	Continuous income from machine sales and shock head consumables
Global patient reach	4,620 active patients worldwide as of December 2025	Operating in 16 countries. 8,000-patient Sapiens Shield programme underway.

> *With a good doctor, the machine is a genius. With CellSonic, a good doctor is a genius..*
>
> **Professor Andrew Hague, Founder, CellSonic**

VII. The Business Model

The structural difference between CellSonic and Novocure is not philosophical. It is financial. And it matters to investors in a way that the clinical comparison alone cannot fully convey.

Novocure Model	CellSonic Model
Device is rented, never sold	Machine is sold once to a clinic
$27,000 per patient per month	Every treatment session generates shock head revenue
Revenue continues only while patient is in treatment	Revenue compounds as the global estate of machines grows
Revenue ends when patient recovers, discontinues, or dies	A clinic that cures patients generates referrals and new patients
Business model requires patients to remain in ongoing treatment	**Business model thrives when patients recover**

Novocure's revenue ends when the patient stops treatment. CellSonic earns on every shock head delivered, regardless of which patient is treated and regardless of the outcome. A machine sold to a clinic in Morocco earns shock head revenue for CellSonic whether it is treating its hundredth patient or its thousandth.

This distinction matters beyond the ethical dimension. A business whose income compounds through a growing global estate of owned machines and a consumable revenue stream from shock heads is structurally more durable than one financially dependent on keeping patients in indefinite treatment.

One year of one Novocure patient at $27,000 per month costs more than a CellSonic machine that a clinic then owns and uses indefinitely on every patient it sees. The maths do not require a spreadsheet.

VIII. The Clinical Evidence

The following cases are drawn from documented CellSonic outcomes. They include one independent cohort study conducted by a researcher with no commercial relationship to CellSonic, one biological age result validated by the Harvard OMICm epigenetic algorithm, and case reports from treating physicians across multiple countries.

Patient	Condition	Documented Outcome
Wendy, age 59	Throat cancer patient	Harvard OMICm epigenetic algorithm: biological age measured at 51.26. Chronological age 59. Biological age reversed by 8.18 years. Systemic mortality risk reduced by 79.03%. Telomere length at 74th percentile for age group. No pharmaceutical intervention.
Tuebingen Cohort	Chronic wounds, 75 patients	Independent study by Dr. Christian Busch MD PhD, University of Tuebingen. No commercial relationship with CellSonic. All 75 patients were therapy-refractory: every prior treatment had failed. 92% showed significant positive response. Published in Cell Physiology and Biochemistry and the Journal of Wound Care.
Ann M.	Stage 2 breast cancer	Tumour markers CA 15.3 dropped below clinical threshold within 14 days of first treatment. Two masses, 13mm and 14mm, documented pre-treatment.
First patient, Bangladesh	Advanced prostate cancer, terminal	Treated in Mumbai, 2016. Blood tests following treatment confirmed absence of cancer.

The Tuebingen study deserves particular attention. Dr. Busch had no financial interest in the outcome. Every patient in the cohort had already exhausted every prior treatment option before CellSonic was applied. A 92 percent positive response rate under those conditions is not anecdotal. It is reproducible evidence from an independent researcher with every incentive to be skeptical.

IX. Sapiens Shield: The Population Plan

Individual cancer treatment is one dimension of what CellSonic is building. Sapiens Shield is the other. It is not speculative. The technology exists today. The diagnosis protocol exists. The treatment exists. What does not yet exist at scale is the infrastructure to deploy it across populations.

A CellSonic diagnosis and treatment takes 20 minutes. Three patients per hour. Twice per year. One clinic can serve 8,000 people. At one million clinics operating worldwide, no person need develop a chronic disease undetected.

The Data Problem That Suppressed a Century of Science

Every major breakthrough in electrical medicine across the past century faced the same structural vulnerability. Data held in a single location could be seized, destroyed, or discredited. Rife's records were lost when his laboratory was destroyed by fire in 1946. Nordenstrom's clinical evidence from 20,000 Chinese patients exists in a jurisdiction most Western institutions never accessed. CellSonic's results live in case reports and one independent cohort study.

The suppression risk is not paranoia. It is a documented pattern across nine decades of independent electrical medicine research. Sapiens Shield removes it entirely.

The Blockchain Architecture

Every treatment delivered through the Sapiens Shield network is recorded immediately into a tamper-proof, distributed blockchain system. The record contains the patient identifier, the condition, the voltage state before and after treatment, the number of sessions, and the outcome.

Once written, the record cannot be altered. Not by the clinic. Not by CellSonic. Not by any government or pharmaceutical company. The data is permanent. The evidence is sovereign.

This is not a product. It is infrastructure. The same category of investment as financial settlement systems and power grids. It compounds in value with every new treatment recorded because every new record strengthens the evidentiary base that no institution can suppress.

The Strategic Entry: Morocco

The pilot programme is Morocco: ten government-affiliated clinics, Ministry of Health-operated blockchain nodes, CellSonic providing devices and protocols. Morocco generates twelve months of government-recorded outcomes. That data becomes the proof of concept for every government seeking to reduce chronic disease costs without pharmaceutical dependency.

Second-tier governments not subject to the pharmaceutical lobbying infrastructure that operates in first-world regulatory environments are the natural early adopters. They have the most to gain and the least institutional resistance to overcome.

What the World Looks Like After Year One

After one year of Sapiens Shield operating in a town of 8,000 people, that town reports no new cancer cases. For the first time in documented history. The data is on a public blockchain. It cannot be dismissed.

The news does not need a journal. People tell people. Every family knows someone in another country. The news reaches politicians because it reaches voters first. Then the phone rings. Then the government wants to scale it.

That is not a marketing plan. That is how science has always spread when institutions failed to carry it.

X. The Investment Case

Why Now

Novocure's fourth FDA approval in February 2026 has permanently legitimised electrical cancer medicine as a recognised oncological modality. The regulatory objection to electric field cancer treatment has been demolished by the FDA's own approvals of a device whose mechanism its scientists admit is not fully understood.

The market has been proven. Novocure generates $655 million in annual revenue from 4,620 patients. The addressable population for CellSonic, which treats 38 conditions and operates at a fraction of the cost per treatment, is orders of magnitude larger.

The evidence architecture that destroyed Rife and marginalised Nordenstrom has been replaced by an immutable blockchain record that no institution can suppress.

The technology is complete, certified, and operating in 16 countries today.

Novocure takes 18 hours a day and makes no mention of voltage. CellSonic lifts cell voltage in 50 seconds and has understood the mechanism for 37 years. We are not behind them. They are behind us.

The Comparable

> *Novocure in 2004 had case reports, a plausible mechanism, and no Phase III trial. They had the physics and needed the funding. CellSonic is at that same position today. The difference is that CellSonic's treatment takes under two minutes rather than 18 hours a day. CellSonic treats 38 documented conditions, not four. CellSonic's safety record runs 40 years through lithotripsy. And CellSonic's business model generates compounding income from shock heads rather than requiring patients to remain in indefinite treatment.*
>
> **Mehdi El Harti, Business Development, CellSonic Ltd.**

What Is Being Built

Component	Status
CellSonic VIPP technology	Complete, operating, CE marked, ISO 13485:2016, FDA registered
Global distributor network	Active in 16 countries across Europe, North America, Middle East, Africa, Asia, Australasia
Clinical evidence base	60+ peer-reviewed publications, 30+ case reports, one independent cohort study
Sapiens Shield programme	8,000-person pilot underway. Morocco government partnership in development.
Blockchain outcome recording	Architecture designed. Deployment tied to Morocco pilot.
Veterinary division	Operating independently, generating its own revenue stream
Beauty division	Operating independently, extending the consumer market for the technology

Contact

Mehdi El Harti | Business Development

mehdi@cellsonicglobal.com | cellsonicltd.com

XI. References

[1] Nordenstrom BEW. Biologically Closed Electric Circuits: Clinical, Experimental and Theoretical Evidence for an Additional Circulatory System. Nordic Medical Publications, Stockholm. 1983.

[2] Cone CD Jr. Combined Adenosine Triphosphate and Membrane Potential Control of Cell Division. NASA Technical Paper NTRS 19700019348. 1970.

[3] Cone CD Jr. Electroosmotic interactions accompanying mitosis initiation in sarcoma cells in vitro. Transactions of the New York Academy of Sciences. 1969;31:404.

[4] Hao Y et al. Tumor treating fields: a comprehensive overview of the underlying molecular mechanism. Expert Review of Molecular Diagnostics. 2022. [Mechanism stated as not fully understood.]

[5] Berkelmann L et al. Tumour-treating fields: investigations on the mechanism of action by electromagnetic exposure of cells in telophase and cytokinesis. Nature Scientific Reports. 2019. [Exact biophysical mechanism stated as not completely understood.]

[6] Kirson ED et al. Disruption of Cancer Cell Replication by Alternating Electric Fields. Cancer Research. 2004;64:3288-3295.

[7] Novocure. Q4 and Full Year 2025 Financial Results. Published February 26, 2026. www.novocure.com.

[8] NCBI. Optune cost documentation. Canadian Agency for Drugs and Technologies in Health review. $27,000 per month submitted fee. NBK602919.

[9] PubMed. Outlook for the use of focused shock waves and pulsed electric fields in the complex treatment of malignant neoplasms. 2007. [Fivefold reduction in cancer cell survival with synchronous electric field and shockwave.]

[10] Busch C, Hague A, Halls G. Total Resolution of a Stage 4 Refractory Diabetic Ulcer Using CellSonic VIPP. Cell Physiology and Biochemistry. 2017.

[11] Busch C. Electrochemical Treatment of Malignant Tumours. Journal of Wound Care. 2017.

[12] Haltiwanger S. The Electrical Properties of Cancer Cells. 2010.

[13] Tennant JL. Healing is Voltage: The Handbook. 2010.

[14] Levin M. Bioelectric Signaling: From Micro-differentiation to Macro-morphogenesis. Cell. 2021.

[15] Halls G PhD. The Architectural Betrayal: A Review of Systematic Biological Failure Induced by Conventional Oncology. Independent Literature Review. 2025. [44 peer-reviewed studies.]

[16] Kaur S et al. Chemotherapy and its Adverse Effects: A Systematic Review. 2022.

[17] Verginadis II et al. Radiotherapy toxicities: mechanisms, management, and future directions. The Lancet. 2025.

[18] Wang K, Tepper JE. Radiation therapy-associated toxicity: etiology, management, and prevention. CA Cancer Journal for Clinicians. 2021.

[19] Al dybiat I et al. Injured tissues favor cancer cell implantation via fibrin deposits on scar zones. 2020.

[20] Jiao Y, Lv Q. Does Primary Tumor Resection Induce Accelerated Metastasis? 2023.

[21] Kwak SB et al. Tumor regionalization after surgery: potential mechanisms and clinical consequences. 2022.

[22] Lynes B. The Cancer Cure That Worked: Fifty Years of Suppression. Marcus Books. 1987. [Royal Rife historical record.]

[23] NIH PMC. Membrane potential and cancer progression. PMC3713347. 2013.

[24] Hague A. Sapiens Shield: CellSonic cures chronic disease in a person, Sapiens Shield stops chronic disease in a population. Journal of Endocrine System and Diabetes. 2022.

[25] Hague A. Cancer Cure: The Protocol and Explanation. Journal of Cancer and Oncology Research. 2020.

[26] Novocure. TTFields therapy reimbursement and commercial availability. novocure.com. August 2025.

This document was prepared by Mehdi El Harti, Business Development, CellSonic Ltd. All clinical outcomes cited are documented and available upon request. CellSonic VIPP technology is CE marked, ISO 13485:2016 and ISO 9001:2017 certified, and FDA registered (No. 3017514970). This document is prepared for sophisticated investors and does not constitute a public offering or a medical claim. All Novocure financial data is drawn from the company's own published quarterly results. All scientific citations are independently verifiable.